Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of the claims in the application:

Listing of Claims:

1. (Original) A compound according to the general formula



or a pharmaceutically acceptable salt thereof, wherein:

R_1 is independently selected from: carboxylic acid ($-CO_2H$); phosphonic acid ($-PO(OH)_2$); phosphamic acid ($-PO(OH)NH_2$); sulphonic acid ($-SO_2OH$); hydroxamic acid ($-CONHOH$); oxamic acid ($-NHCOCO_2H$); and malonamic acid ($-NHCOCH_2CO_2H$), or any other possible bioisosteric equivalent of the groups above;

R_2 and R_3 are the same or different and independently selected from: chlorine; bromine; iodide; C_{1-4} alkyl, said alkyl, or a bioisosteric equivalent optionally substituted with 0, 1, 2 or 3 groups of R^a which groups may be the same or different;

R_4 and R_6 are the same or different and independently selected from: hydrogen; halogen; C_{1-4} alkyl; or a bioisosteric

equivalent optionally substituted with 0, 1, 2 or 3 groups of R^a which groups may be the same or different;

R_5 is selected from: C_{6-10} aryl; C_{1-9} heteroaryl, said aryl; and heteroaryl optionally substituted with 0, 1, 2 or 3 groups of R^b which groups may be the same or different;

R^a represents fluorine or chlorine;

R^b represents a member selected from the group of: halogen; -CN; $-CO_2H$; -CHO; $-NH_2$; C_{1-4} alkyl; C_{2-4} alkenyl; C_{2-4} alkynyl; C_{1-4} alkoxy; C_{2-4} alkenoxy; C_{2-4} alkynoxy; C_{1-4} alkylthio; C_{2-4} alkenylthio; C_{2-4} alkynylthio; C_6 aryl; C_{1-5} heteroaryl; C_{3-6} cycloalkyl; $-NH(C_{1-4})$; $-N(C_{1-4})_2$; $-NH(C_6aryl)$; $-N(C_6aryl)_2$; $-NH(C_{1-5}$ heteroaryl); and $-N(C_{1-5}$ heteroaryl$)_2$ or a bioisosteric equivalent;

n is an integer of 1, 2 or 3;

included for the variables above are all the possible stereoisomers thereof; prodrug ester forms thereof; and radioactive forms thereof.

2. (Original) A compound according to claim 1 wherein R_1 is carboxylic acid ($-CO_2H$).

3. (Currently Amended) A compound according to claim 1 ~~or 2~~ wherein R_2 and R_3 is bromine or chlorine.

4. (Currently Amended) A compound according to ~~any one of claims 1 to 3~~ claim 1, wherein R_4 is isopropyl and R_6 is hydrogen.

5. (Currently Amended) A compound according to ~~any one of claims 1, 2 or 4~~ claim 1, wherein R_2 and R_3 is bromine.

6. (Currently Amended) A compound according to ~~any one of claims 1 to 5~~ claim 1, which is:

{4,6-Dibromo-5-[3-isopropyl-4-(naphthalen-2-yl-methoxy)phenoxy]indan-1-yl}-acetic acid;

{4,6-Dibromo-5-[4-(4-fluorobenzyloxy)-3-isopropylphenoxy]indan-1-yl}acetic acid;

{4,6-Dibromo-5-[3-isopropyl-4-(5-methylisoxazol-3-ylmethoxy)phenoxy]indan-1-yl}acetic acid;

{4,6-Dibromo-5-[3-isopropyl-4-(pyridin-2-yl-methoxy)phenoxy]indan-1-yl}acetic acid;

4,6-Dibromo-5-[3-isopropyl-4-(5-phenyl-[1,2,4]oxadiazol-3-ylmethoxy)phenoxy]-indan-1-yl} acetic acid;

4-[4-(4,6-Dibromo-1-carboxymethyl-indan-5-yloxy)-2-isopropylphenoxymethyl]-benzoic acid;

(4,6-Dibromo-5-4-[2-(1*H*-indol-2-yl)ethoxy]-3-isopropylphenoxy}indan-1-yl)acetic acid;

(4,6-Dibromo-5-[3-isopropyl-4-(5-thiophen-3-yl-[1,2,4]oxadiazol-3-yl-methoxy)-phenoxy]indan-1-yl}acetic acid;

{5-[4-(4-Amino-6-phenylamino[1,3,5]triazin-2-ylmethoxy)-3-isopropylphenoxy]-4,6-dibromoindan-1-yl}acetic acid;

{4,6-Dibromo-5-[3-isopropyl-4-(5-methyl-2-phenyloxazol-4-ylmethoxy)phenoxy]-indan-1-yl} acetic acid;

{4,6-Dibromo-5-[4-(3,5-dimethylisoxazol-4-ylmethoxy)-3-isopropylphenoxy]-indan-1-yl}acetic acid;

and pharmaceutically acceptable salts thereof, and stereoisomers thereof.

7. (Currently Amended) A compound according to ~~any one of claims 1 to 6,~~ claim 1, which have one or more asymmetric centers and can exist in the form of racemates, single and multiple enantiomers, as individual diastereomers, with all possible isomers, and mixtures thereof.

8. (Currently Amended) A compound according to ~~any one of claims 1 to 7~~ claim 1, for use in medical therapy.

9. (Currently Amended) A pharmaceutical composition comprising an effective amount of a compound according to ~~any one of claims 1 to 7~~ claim 1, or a pharmaceutically effective salt thereof, together with a pharmaceutically acceptable carrier.

10. (Currently Amended) A method for preventing, inhibiting or treating a disease which is dependent on the expression of a T_3 regulated gene or associated with metabolic dysfunction, which comprises administering to a patient in need of treatment a therapeutically effective amount of a compound according to ~~any one of claims 1 to 7~~ claim 1.

11. (Original) The method according to claim 10 wherein the disease is selected from cardiac arrythmias, thyrotoxicosis, subclinical hyperthyrodis, certain skin disorders, and certain liver diseases.

12. (Original) The method according to claim 11 wherein the disease is a skin disorder or skin disease.

13. (Original) The method according to claim 12 wherein the skin disorder or skin disease is selected from: keloids, lichen planus, ichtyosis, acne, psoriasis, Dernier's disease, eczema, atopic dermatitis, chloracne, pityriasis, and hirsuitism.

14. (Original) The method according to claim 11 wherein the disease is a liver disorder or liver disease.

15. (Original) The method according to claim 14 wherein the liver disorder or liver disease is selected from: chronic alcoholism, acute hepatitis, hepatitis C-induced liver cirrhosis, and liver fibrosis.

16. (Currently Amended) A method to treat ~~certain~~ skin disorders or diseases comprising the step of administering to a patient suffering skin disorders or diseases a pharmaceutical composition comprising ~~by the use of~~ a compound according to ~~any one of claims 1 to 7~~ claim 1 in a combination with a retoid or a Vitamin D analog.

17 - 24. (Cancelled).